Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a randomized clinical trial

Maria E. Cabanillas, Hagop Kantarjian, Deborah A. Thomas, Gloria N. Mattiuzzi, Michael E. Rytting, Eduardo Bruera, Lianchun Xiao, B. Nebiyou Bekele, Maria C. Foudray, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia. This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes (PRBCs) transfused, and the secondary objective was to study the effects of epoetin alpha on quality of life (QOL) and complete remission (CR) rates. METHODS: Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy. QOL was assessed by using the Edmonton Symptom Assessment Scale (ESAS) and the Functional Assessment of Cancer Therapy (FACT)-Anemia questionnaires. RESULTS: Fifty-five patients were randomized to receive epoetin alpha, and 54 patients received no epoetin. Transfusion data were available for 79 of 81 evaluable patients (98%) who completed the treatment/observation period. The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met. A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P =.04). There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments. The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha. CONCLUSIONS: Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration. No difference in QOL was observed.

Original languageEnglish (US)
Pages (from-to)848-855
Number of pages8
JournalCancer
Volume118
Issue number3
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

Epoetin Alfa
Erythrocyte Transfusion
Burkitt Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Randomized Controlled Trials
Quality of Life
Anemia
Symptom Assessment
Drug Therapy
Neoplasms
Leukemia

Keywords

  • anemia
  • epoetin
  • leukemia
  • progression-free survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma : Results of a randomized clinical trial. / Cabanillas, Maria E.; Kantarjian, Hagop; Thomas, Deborah A.; Mattiuzzi, Gloria N.; Rytting, Michael E.; Bruera, Eduardo; Xiao, Lianchun; Bekele, B. Nebiyou; Foudray, Maria C.; Cortes, Jorge E.

In: Cancer, Vol. 118, No. 3, 01.02.2012, p. 848-855.

Research output: Contribution to journalArticle

Cabanillas, Maria E. ; Kantarjian, Hagop ; Thomas, Deborah A. ; Mattiuzzi, Gloria N. ; Rytting, Michael E. ; Bruera, Eduardo ; Xiao, Lianchun ; Bekele, B. Nebiyou ; Foudray, Maria C. ; Cortes, Jorge E. / Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma : Results of a randomized clinical trial. In: Cancer. 2012 ; Vol. 118, No. 3. pp. 848-855.
@article{4afaca9d1aa9409ea6a8f5b1ba620e6f,
title = "Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a randomized clinical trial",
abstract = "BACKGROUND: Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia. This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes (PRBCs) transfused, and the secondary objective was to study the effects of epoetin alpha on quality of life (QOL) and complete remission (CR) rates. METHODS: Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy. QOL was assessed by using the Edmonton Symptom Assessment Scale (ESAS) and the Functional Assessment of Cancer Therapy (FACT)-Anemia questionnaires. RESULTS: Fifty-five patients were randomized to receive epoetin alpha, and 54 patients received no epoetin. Transfusion data were available for 79 of 81 evaluable patients (98{\%}) who completed the treatment/observation period. The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met. A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P =.04). There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments. The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha. CONCLUSIONS: Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration. No difference in QOL was observed.",
keywords = "anemia, epoetin, leukemia, progression-free survival",
author = "Cabanillas, {Maria E.} and Hagop Kantarjian and Thomas, {Deborah A.} and Mattiuzzi, {Gloria N.} and Rytting, {Michael E.} and Eduardo Bruera and Lianchun Xiao and Bekele, {B. Nebiyou} and Foudray, {Maria C.} and Cortes, {Jorge E.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1002/cncr.26341",
language = "English (US)",
volume = "118",
pages = "848--855",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma

T2 - Results of a randomized clinical trial

AU - Cabanillas, Maria E.

AU - Kantarjian, Hagop

AU - Thomas, Deborah A.

AU - Mattiuzzi, Gloria N.

AU - Rytting, Michael E.

AU - Bruera, Eduardo

AU - Xiao, Lianchun

AU - Bekele, B. Nebiyou

AU - Foudray, Maria C.

AU - Cortes, Jorge E.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - BACKGROUND: Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia. This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes (PRBCs) transfused, and the secondary objective was to study the effects of epoetin alpha on quality of life (QOL) and complete remission (CR) rates. METHODS: Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy. QOL was assessed by using the Edmonton Symptom Assessment Scale (ESAS) and the Functional Assessment of Cancer Therapy (FACT)-Anemia questionnaires. RESULTS: Fifty-five patients were randomized to receive epoetin alpha, and 54 patients received no epoetin. Transfusion data were available for 79 of 81 evaluable patients (98%) who completed the treatment/observation period. The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met. A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P =.04). There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments. The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha. CONCLUSIONS: Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration. No difference in QOL was observed.

AB - BACKGROUND: Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia. This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes (PRBCs) transfused, and the secondary objective was to study the effects of epoetin alpha on quality of life (QOL) and complete remission (CR) rates. METHODS: Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy. QOL was assessed by using the Edmonton Symptom Assessment Scale (ESAS) and the Functional Assessment of Cancer Therapy (FACT)-Anemia questionnaires. RESULTS: Fifty-five patients were randomized to receive epoetin alpha, and 54 patients received no epoetin. Transfusion data were available for 79 of 81 evaluable patients (98%) who completed the treatment/observation period. The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met. A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P =.04). There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments. The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha. CONCLUSIONS: Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration. No difference in QOL was observed.

KW - anemia

KW - epoetin

KW - leukemia

KW - progression-free survival

UR - http://www.scopus.com/inward/record.url?scp=84856213182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856213182&partnerID=8YFLogxK

U2 - 10.1002/cncr.26341

DO - 10.1002/cncr.26341

M3 - Article

C2 - 21751205

AN - SCOPUS:84856213182

VL - 118

SP - 848

EP - 855

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -